LENZ Therapeutics, Inc. (LENZ) income statement
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3061% below fair value
$2.96−0.38 (-11.23%)
Close on Nov 20, 2026Market cap $93.16MP/E –Yield –
LENZ Therapeutics, Inc. financial ratios
See a number that looks wrong?